| Name | AM2201 Benzimidazole Analog (FUBIMINA) |
|---|
| Formal Name | (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone; FUBIMINA; FTHJ |
|---|
| SMILES | O=C(C1=NC2=C(C=CC=C2)N1CCCCCF)C3=CC=CC4=CC=CC=C43 |
|---|
| InChI Key | KUESSZMROAFKQJ-UHFFFAOYSA-N |
|---|
| InChI Code | InChI=1S/C23H21FN2O/c24-15-6-1-7-16-26-21-14-5-4-13-20(21)25-23(26)22(27)19-12-8-10-17-9-2-3-11-18(17)19/h2-5,8-14H,1,6-7,15-16H2 |
|---|
| Description | AM2201 Benzimidazole analog is a synthetic cannabinoid designer drug that introduces a benzimidazole in place of the indole central core observed in other structurally similar cannabinoids such as JWH-018 and AM2201. Although the physiological and toxicological properties of this AM2201 benzimidazole analog have not yet been tested, other benzimidazole analogs have been detected in herbal blends and have been shown to be selective CB2 receptor agonists. The des-fluoro cannabinoid JWH-018 benzimidazole analog was previously identified simultaneously by the Canada Border Services Agency and USACIL in herbal smoking mixtures in late 2013, and subsequently confirmed through independent reference standard synthesis at Cayman Chemical Company. |
|---|
Status |
Verified |
|---|
| Submitted | 2014-07-22 |
|---|
| Submitted By | Cayman Chemical
Georgia Bureau of Investigation, Headquarters Laboratory – Decatur, GA |
|---|
| Published | 2014-10-15 |
|---|
| Contact | Paul D. Kennedy, PhD. at Cayman Chemical |
|---|
| Product Details | Link |
|---|
Monograph |
Download the AM2201 Benzimidazole Analog (FUBIMINA) Monograph |
|---|
|
|
